Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:36:25.706Z.
Calculation as of: 2026-10-06T15:36:25.706Z.
Quote observation: 2026-10-06T15:34:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6caa0376099c5ebdf209f9b018955c4d65987c3db8176dc1b5ff0a1c5aca19bf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$500.37M
PS Ratio
1640.09
TTM Avg
1950.14
3Y Avg
2119.90
5Y Avg
1775.57
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bright Minds Biosciences Inc. (DRUG) | $479.85M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $473.85M | N/A | 8.89 | 8.89 | 8.89 |
| Cerus Corporation (CERS)vs › | $475.46M | 2.15 | 2.12 | 1.95 | 3.28 |
| Arvinas, Inc. (ARVN)vs › | $483.04M | 1.53 | 3.28 | 9.68 | 27.67 |
| Kamada Ltd. (KMDA)vs › | $468.48M | 2.44 | 2.55 | 2.28 | 2.17 |
| Puma Biotechnology, Inc. (PBYI)vs › | $490.16M | 2.12 | 1.60 | 1.05 | 0.88 |
| Evolus, Inc. (EOLS)vs › | $491.28M | 1.55 | 1.38 | 2.53 | 3.18 |
| NRC Health (NRC)vs › | $463.75M | 3.31 | 2.88 | 3.66 | 4.95 |
| Oculis Holding AG (OCS)vs › | $500.37M | 1640.09 | 1950.14 | 2119.90 | 1775.57 |
| Ovid Therapeutics Inc. (OVID)vs › | $453.54M | 286.50 | 36.80 | 225.33 | 298.60 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
Reported statement amounts were converted from CAD to USD using the stored FMP exchange-rate calculation.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-23 |
| Q1 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-13 |
| Q2 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-20 |
| Q3 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-17 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
